Gland Surgery （Gland Surg; GS，Print ISSN 2227-684X; Online ISSN 2227-8575）于2012年5月推出，于2014年6月在PubMed / PubMed Central 收錄，2018年12月收錄 SCIE，是一本開放獲取，同行評(píng)審的期刊重點(diǎn)關(guān)注腺體手術(shù)近期的科學(xué)進(jìn)展。2018年GS的影響因子為1.922。作為雙月刊出版的期刊，它旨在提供有關(guān)腺體疾病的診斷，預(yù)防和治療的前沿研究結(jié)果和實(shí)用信息，如乳腺癌，甲狀腺癌，腎上腺癌，胰腺手術(shù)和其他相關(guān)領(lǐng)域。致力于理解和治療腺體疾病，這個(gè)多學(xué)科期刊發(fā)表文章，描述來自一系列領(lǐng)域的腺體疾病的基礎(chǔ)，轉(zhuǎn)化和臨床研究，如生物標(biāo)志物，影像學(xué)，病理學(xué)，生物學(xué)和介入放射學(xué)等。讀者可望獲得新的了解腺體疾病的診斷，治療方法和預(yù)后。

Gland Surgery (Gland Surg; GS, Print ISSN 2227-684X; Online ISSN 2227-8575), launched in May 2012, indexed in PubMed/PubMed Central in June 2014 and SCIE in December 2018, is an open access, peer-reviewed journal focused on recent scientific advances in gland surgery. The 2018 Impact Factor for GS is 1.922.As a bimonthly published journal, it aims at providing cutting-edge findings and practical information on diagnosis, prevention, and treatment of gland diseases, such as breast, thyroid, adrenal, pancreas surgery and other related fields. Dedicated to the understanding and treatment of gland diseases, this multidisciplinary periodical publishes articles that describe basic, translational and clinical research of gland disease from a range of fields as biomarkers, imaging, pathology, biology and interventional radiology etc. Readers can expect to gain new insights into diagnosis, therapeutic approaches and prognosis of gland diseases.